Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18765867 | BENZOATE DERIVATIVES | July 2024 | August 2025 | Allow | 13 | 1 | 1 | No | No |
| 18755058 | PCNA INHIBITORS | June 2024 | July 2025 | Allow | 12 | 1 | 0 | No | No |
| 18643710 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | April 2024 | August 2025 | Allow | 16 | 1 | 1 | No | No |
| 18606778 | 3-(3-FLUOROPHENYL)-5-(4-METHOXYBENZYLTHIO)-4-PHENYL-4H-1,2,4-TRIAZOLE AS AN ANTIMICROBIAL COMPOUND | March 2024 | December 2024 | Allow | 9 | 1 | 1 | No | No |
| 18428190 | PROBE RELATED REAGENTS AND METHODS | January 2024 | January 2026 | Allow | 24 | 2 | 1 | No | No |
| 18423156 | CARDIAC SARCOMERE INHIBITORS | January 2024 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18420478 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | January 2024 | February 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18390494 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | December 2023 | August 2025 | Allow | 20 | 2 | 0 | No | No |
| 18526028 | ELECTROPHILIC NITROALKENE BENZOIC ACID DERIVATES AS THERAPEUTIC DRUGS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE CONDITIONS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18522995 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | November 2023 | April 2025 | Allow | 16 | 2 | 0 | No | No |
| 18382812 | 3-(3-FLUOROPHENYL)-5-(4-METHOXYBENZYLTHIO)-4-PHENYL-4H-1,2,4-TRIAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | August 2024 | Abandon | 10 | 1 | 1 | No | No |
| 18381291 | ETHYL 6-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)HEXANOATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 0 | 1 | No | No |
| 18381069 | ETHYL {[4-BENZOYL-5-(3-FLUOROPHENYL)-4H-1,2,4-TRIAZOL-3-YL]THIO}ACETATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 0 | 1 | No | No |
| 18370519 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | September 2023 | September 2024 | Allow | 12 | 2 | 1 | No | No |
| 18363714 | Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging | August 2023 | January 2026 | Allow | 30 | 1 | 0 | No | No |
| 18320241 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | May 2023 | October 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18296742 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | April 2023 | January 2026 | Allow | 33 | 6 | 1 | Yes | No |
| 18029754 | TRIALKYL SULFONIUM SALTS | March 2023 | March 2026 | Allow | 35 | 1 | 1 | No | No |
| 18028878 | NOVEL NAPHTHALIMIDE SULFONATE DERIVATIVE, AND PHOTOACID GENERATOR AND PHOTORESIST COMPOSITION WHICH COMPRISE SAME | March 2023 | January 2026 | Allow | 34 | 0 | 1 | No | No |
| 18028184 | METHOD FOR PRODUCING ASYMMETRIC LINEAR CARBONATE | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18108045 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | February 2023 | March 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18107786 | MODULATORS OF ALPHA-1 ANTITRYPSIN | February 2023 | September 2025 | Abandon | 32 | 0 | 1 | No | No |
| 18103371 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18103319 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18103180 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18102983 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | January 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18159647 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | January 2023 | September 2025 | Allow | 32 | 2 | 2 | No | No |
| 18155399 | Analogs of Nitrofuran Antibiotics to Combat Resistance | January 2023 | October 2025 | Allow | 33 | 3 | 0 | No | No |
| 18154520 | BENZOATE DERIVATIVES | January 2023 | April 2024 | Allow | 15 | 1 | 1 | No | No |
| 18085869 | METHODS OF TREATING PROSTATE CANCER | December 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18078630 | DISELENIDE-BASED ORGANIC PROTECTIVE FILMS | December 2022 | October 2023 | Allow | 10 | 2 | 1 | No | No |
| 18062959 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, IMAGE PICKUP ELEMENT, AND IMAGE PICKUP APPARATUS | December 2022 | May 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18076422 | Compound, And Method For Producing Regulatory T Cells | December 2022 | December 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17986207 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | November 2022 | September 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17982664 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | November 2022 | July 2024 | Allow | 21 | 2 | 1 | No | No |
| 17978848 | SOLID FORMS OF(Z)-4-(5-((3-BENZYL-4-OXO-2-THIOXOTHIAZOLIDIN-5-YLIDENE)METHYL)FURAN-2-YL)BENZOIC ACID | November 2022 | October 2024 | Allow | 24 | 2 | 0 | No | No |
| 18045390 | STAT DEGRADERS AND USES THEREOF | October 2022 | January 2023 | Allow | 3 | 0 | 0 | No | No |
| 17907152 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | September 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17931377 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | September 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17939512 | PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | September 2022 | May 2023 | Abandon | 8 | 0 | 1 | No | No |
| 17889047 | ESTERS OF A RETINOID AND A TOCOPHEROL OR TERT-BUTYLHYDROQUINONE AND PREPARATIONS THEREOF | August 2022 | February 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17884292 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | August 2022 | June 2025 | Allow | 35 | 1 | 1 | No | No |
| 17875982 | IONIZABLE LIPIDOIDS AND THEIR USES | July 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17794971 | MESOIONIC INSECTICIDES | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17792005 | AZIRIDINYL FUNCTIONAL COMPOUND | July 2022 | February 2026 | Allow | 43 | 2 | 1 | Yes | No |
| 17862071 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | July 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17849949 | Cytotoxic Actin-Targeting Compounds | June 2022 | November 2024 | Allow | 28 | 2 | 0 | No | No |
| 17849281 | RESMETIROM CRYSTAL, PREPARATION METHOD FOR SAME, AND USES THEREOF | June 2022 | August 2025 | Allow | 37 | 1 | 0 | No | No |
| 17787992 | DEUCRAVACITINIB CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17807389 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17787273 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17784969 | COMPOUNDS FOR INHIBITING NEOVASCULARIZATION FACTORS AND USE THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 0 | No | No |
| 17784405 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17830158 | ANTI-VIRAL DRUG | June 2022 | November 2024 | Allow | 30 | 1 | 1 | No | No |
| 17780969 | A PHARMACEUTICAL ORAL DOSAGE FORM OF Q203 | May 2022 | February 2026 | Allow | 45 | 1 | 0 | No | No |
| 17780047 | CANNABIGEROL DERIVATIVES AND USE THEREOF AS CANNABINOID RECEPTOR MODULATORS | May 2022 | April 2024 | Allow | 23 | 2 | 0 | No | No |
| 17752649 | BICYCLIC COMPOUNDS | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17779491 | LIPOPHOSPHONOXINS, THEIR PREPARATION AND USE | May 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17748292 | COMPOSITION OF A LIPOPHILIC AGENT FOR SOLUTION PHASE SYNTHESIS OF BIOMOLECULES | May 2022 | August 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17746678 | INHIBITION OF NEUROLOGICAL INJURIES DUE TO INFECTIONS VIA ADMINISTRATION OF BUTANETAP AND ANALOGS THEREOF | May 2022 | December 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17738166 | PROTEIN COMPLEX COMPRISING NON-PEPTIDYL POLYMER-COUPLED FATTY ACID DERIVATIVE COMPOUND AS LINKER AND PREPARATION METHOD THEREFOR | May 2022 | March 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17662246 | INDOLE AHR INHIBITORS AND USES THEREOF | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17736669 | STAT DEGRADERS AND USES THEREOF | May 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17732724 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | April 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17661182 | HETERO-BICYCLIC INHIBITORS OF KRAS | April 2022 | June 2023 | Allow | 14 | 2 | 1 | No | Yes |
| 17730948 | PCNA INHIBITORS | April 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17729652 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION | April 2022 | April 2024 | Allow | 24 | 0 | 1 | No | No |
| 17717305 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | April 2022 | January 2026 | Allow | 45 | 2 | 1 | No | No |
| 17704892 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | March 2022 | April 2025 | Allow | 36 | 3 | 0 | No | No |
| 17654547 | Bromodomain Inhibitors | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17687188 | CHEMICAL COMPOUNDS | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17685778 | CARDIAC SARCOMERE INHIBITORS | March 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17640135 | MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION | March 2022 | July 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17668519 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | February 2022 | February 2025 | Allow | 36 | 1 | 0 | No | No |
| 17587304 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | January 2022 | May 2025 | Allow | 40 | 2 | 1 | No | No |
| 17597894 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | January 2022 | August 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17627799 | METHOD OF INDUCING BACTERIAL HEAT SENSITIVITY | January 2022 | January 2026 | Abandon | 48 | 0 | 1 | No | No |
| 17575080 | COMPOSITIONS AND METHODS RELATING TO NOVEL SULFONO-gamma-AA PEPTIDES | January 2022 | August 2024 | Allow | 31 | 2 | 1 | No | No |
| 17621950 | POLYMORPHS OF 1-(2-((((TRANS)-3-FLUORO-1-(3-FLUOROPYRIDIN-2-YL)CYCLOBUTYL)METHYL)AMINO)PYRIMIDIN-5-YL)-1H-PYRROLE-3-CARBOXAMIDE | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17621502 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | December 2021 | August 2025 | Allow | 44 | 1 | 1 | No | No |
| 17556188 | TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR | December 2021 | May 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17595819 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | November 2021 | April 2025 | Abandon | 40 | 0 | 0 | No | No |
| 17613800 | Pain Relieving Spray | November 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17612713 | CARBENE MASS TAGGING | November 2021 | December 2025 | Allow | 60 | 2 | 1 | No | No |
| 17595537 | AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS | November 2021 | April 2025 | Abandon | 41 | 0 | 0 | No | No |
| 17452786 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | October 2021 | May 2024 | Allow | 30 | 1 | 0 | No | No |
| 17605750 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17605780 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | October 2021 | December 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17506748 | IMMUNOSUPPRESSIVE DOSAGE FORMS AND METHODS OF USE | October 2021 | January 2026 | Abandon | 51 | 2 | 1 | Yes | No |
| 17506614 | DUAL-RESPONSIVE NANOPARTICLES FOR ENHANCED ANTIBACTERIAL EFFICACY | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17503961 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE | October 2021 | February 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17500479 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEOLYTIC ACTIVATION OF VIRUSES | October 2021 | November 2025 | Abandon | 49 | 2 | 2 | Yes | No |
| 17499433 | RAPAMYCIN DERIVATIVES | October 2021 | March 2024 | Allow | 29 | 1 | 0 | No | No |
| 17602412 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | October 2021 | July 2025 | Allow | 45 | 1 | 1 | No | No |
| 17489149 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | September 2021 | December 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17599785 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | September 2021 | March 2026 | Abandon | 54 | 2 | 1 | No | No |
| 17442206 | NOVEL DEPSIDE DIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | September 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17480424 | ENZYME INHIBITORS | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17479438 | ASYMMETRIC METAL COMPLEX AS AN ACTIVE MATERIAL OF A FLOW BATTERY | September 2021 | September 2024 | Allow | 36 | 2 | 1 | No | No |
| 17475733 | HETEROCYCLIC COMPOUND | September 2021 | April 2025 | Allow | 43 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, PO-CHIH.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHEN, PO-CHIH works in Art Unit 1621 and has examined 217 patent applications in our dataset. With an allowance rate of 79.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner CHEN, PO-CHIH's allowance rate of 79.7% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHEN, PO-CHIH receive 2.15 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, PO-CHIH is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +3.4% benefit to allowance rate for applications examined by CHEN, PO-CHIH. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 23.4% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.4% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 38.5% are granted (fully or in part). This grant rate is in the 27% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 17.3% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.